https://obesityweek.org/
https://lumos-pharma.com/
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Positive-Results-of-a-Double-Blind-Study-of-Subcutaneous-Low-Dose-Interleukin-2-LD-IL-2-in-Alzheimers-Disease-AD-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-Conference-CTAD24-in-Madrid-Spain/default.aspx
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Announces-Conference-Call-to-Report-Results-from-an-Investigator-Initiated-Phase-2-Trial-of-Low-Dose-Interleukin-2-in-Patients-with-Mild-to-Moderate-Alzheimers-Disease/default.aspx
https://s201.q4cdn.com/307844724/files/doc_presentations/2024/Oct/29/CTAD-LD-IL-2-Data-Presentation-102924-F.pdf
https://event.choruscall.com/mediaframe/webcast.html?webcastid=xpdYyUGI
https://finance.yahoo.com/news/coya-therapeutics-high-dose-interleukin-183652461.html
https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-host-call-review-full-data-set-including-win-ratio
https://www.fortressbiotech.com/investors/news-events/press-releases/detail/672/journey-medical-corporation-announces-dfd-29-data-presented
https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update
https://www.cnbc.com/video/2024/10/24/viking-therapeutics-shares-soar-on-fresh-weight-loss-medication-hopes.html#:~:text=Fast%20Money-,Viking%20Therapeutics'%20shares%20soar%20on%20fresh%20weight%2Dloss%20medication%20hopes,jumping%20on%20weight%2Dloss%20hopes.
https://ir.achievelifesciences.com/news-events/press-releases/detail/211/achieve-life-sciences-to-announce-third-quarter-financial
https://investors.grail.com/news-releases/news-release-details/grail-announce-third-quarter-2024-financial-results
https://investors.x4pharma.com/node/11351/pdf

